{"entity":{"id":"nct07486089","kind":"trial","name":"Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)","aka":[],"tldr":"A phase 1/2 trial of Fludarabine in her2-positive breast cancer and triple-negative breast cancer, run by Beijing Biotech, now recruiting.","summary":"Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) is a phase 1/2 interventional study registered as NCT07486089 by Beijing Biotech, with 60 participants planned, started 2026-02-02 and due to reach its primary completion in 2027-02-14. Interventions recorded: Dual-target CAR-NK cells (EB-DT-CAR-NK), Lymphodepleting chemotherapy, Supportive care. Conditions listed: Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07486089","url":"https://clinicaltrials.gov/study/NCT07486089"}],"tags":["ctgov-ingest"],"related":[],"cancers":["breast-her2-positive","tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":["fludarabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07486089","phase":"1/2","setting":"Phase 1/2, Biomarker-guided, Open-label Study of Allogeneic Dual-target CAR-NK Cells Directed Against HER2/ERBB2, MUC1, and/or ROR1 in Patients With Advanced or Metastatic Breast Cancer (Including HER2-positive and Triple-negative Disease).","sponsor":"Beijing Biotech","enrolled":60,"outcomes":[]},"route":"/trials/nct07486089/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"drug":[{"id":"fludarabine","kind":"drug","name":"Fludarabine","route":"/drugs/fludarabine/"}]}}